TY  - JOUR
AU  - Feliu, Jaime
AU  - Garcia-Carbonero, Rocio
AU  - Capdevila, Jaume
AU  - Guasch, Inmaculada
AU  - Alonso-Orduna, Vicente
AU  - Lopez, Carlos
AU  - Garcia-Alfonso, Pilar
AU  - Castanon, Carmen
AU  - Sevilla, Isabel
AU  - Cerezo, Laura
AU  - Conill, Carles
AU  - Quintana-Angel, Begona
AU  - Sanchez, Maria E
AU  - Ghanem, Ismael
AU  - Martin-Richard, Marta
AU  - Lopez-Gomez, Miriam
AU  - Leon, Ana
AU  - Caro, Monica
AU  - Fernandez, Teresa
AU  - Maurel, Joan
PY  - 2019
DO  - 10.1002/cam4.2722
UR  - http://hdl.handle.net/10668/14847
T2  - Cancer medicine
AB  - VITAL, a phase II single-arm study, aimed to evaluate efficacy and safety of panitumumab addition to 5-fluorouracil (5-FU), mitomycin-C (MMC) and radiotherapy (RT) in patients with localized squamous cell carcinoma of the anal canal (SCCAC). Adult,...
LA  - en
KW  - chemotherapy
KW  - radiotherapy
KW  - rectal cancer
KW  - target therapy
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Anus Neoplasms
KW  - Chemoradiotherapy, Adjuvant
KW  - Disease-Free Survival
KW  - Female
KW  - Fluorouracil
KW  - Follow-Up Studies
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Mitomycin
KW  - Neoadjuvant Therapy
KW  - Neutropenia
KW  - Panitumumab
KW  - Proctectomy
KW  - Radiodermatitis
KW  - Severity of Illness Index
KW  - Survival Rate
TI  - VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).
TY  - research article
VL  - 9
ER  -